Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18–75, and have confirmed stomach or gastroesophageal junction (GEJ) cancer
- Have had curative stomach surgery with D2 lymph node removal and no/limited remaining tumor (R0 or R1)
- Have stage III cancer (8th AJCC) and currently have no detectable cancer on scans in the last 28 days
- Be able to do daily activities fairly well (ECOG 0–1) and have life expectancy >6 months
- Have recent blood tests within required ranges for bone marrow, liver, and kidney function
- Not have recent major bleeding, brain metastases, uncontrolled heart problems, blood clots in the last 6 months, or the need for corticosteroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can help treat stomach or gastroesophageal junction cancer. It is for people whose cancer has not spread to other organs and who are well enough to have surgery.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This study tests whether personalized adjuvant therapy, guided by ctDNA levels in your blood, can reduce the risk of cancer returning after surgery for stage III or IVA stomach or gastroesophageal junction cancer. It is for individuals with HER2-negative disease who are candidates for surgery and have not had prior treatment.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.